Literature DB >> 2226325

Hypoglycemic potency and metabolic clearance rate of intravenously administered human proinsulin and metabolites.

H Tillil1, B H Frank, A H Pekar, C Broelsch, A H Rubenstein, K S Polonsky.   

Abstract

Since circulating proinsulin has been suggested to be important in the pathogenesis of noninsulin-dependent diabetes, and biosynthetic human proinsulin (HPI) may have a therapeutic role in patients with diabetes mellitus, the biological activity of proinsulin metabolites is of potential significance. Moreover, recent studies have suggested that the majority of circulating proinsulin immunoreactivity consists of metabolites. We, therefore, compared the blood glucose-lowering ability and MCR of the two proinsulin metabolites des-(31,32)HPI and des-(64,65)HPI with intact HPI in seven anesthetized dogs after an overnight fast. Intravenous bolus injections of 12.5 micrograms HPI/kg BW and equimolar amounts of des-(31,32)HPI and des-(64,65)HPI were given on three separate occasions. In addition to blood glucose, des-(31,33)HPI, des-(64,65)HPI, and HPI were measured using an insulin RIA and peptide-specific standard curves. Kinetic parameters were derived by fitting two exponentials to the respective decay curves. The MCR of HPI (3.3 +/- 0.1 ml/kg.min) was significantly lower (P less than 0.05) than that of des-(64,65)HPI (6.4 +/- 0.6 ml/kg.min), but was not significantly different from that of des-(31,32)HPI (3.8 +/- 0.4 ml/kg.min). The MCR of biosynthetic insulin (17.2 +/- 1.8 ml/kg.min), as measured in three of the dogs, was higher than that of HPI or the two metabolites. The blood glucose-lowering ability (defined as nadir glucose/fasting glucose, expressed as a percentage) of des-(64,65)HPI (49.3 +/- 5.0%) was significantly greater (P less than 0.05) than that of intact HPI (87 +/- 2.2%), and the glucose-lowering ability of des-(31,32)HPI (75.2 +/- 3.8%) was intermediate. In conclusion, HPI metabolites are more biologically active than intact HPI. The extent of in vivo conversion of proinsulin to metabolites may enhance the biological activity of proinsulin and, thus, have physiological, pathophysiological, and therapeutic significance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2226325     DOI: 10.1210/endo-127-5-2418

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Pharmacokinetic considerations of new insulin formulations and routes of administration.

Authors:  A Hoffman; E Ziv
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

2.  The structure of a mutant insulin uncouples receptor binding from protein allostery. An electrostatic block to the TR transition.

Authors:  Zhu-li Wan; Kun Huang; Shi-Quan Hu; Jonathan Whittaker; Michael A Weiss
Journal:  J Biol Chem       Date:  2008-05-20       Impact factor: 5.157

3.  Obesity-related markers and breast cancer in CPS-II Nutrition Cohort.

Authors:  Mia M Gaudet; Alpa V Patel; Lauren R Teras; Juzhong Sun; Peter T Campbell; Victoria L Stevens; Eric J Jacobs; Susan M Gapstur
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

4.  Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients.

Authors:  Michael R Rickels; Rebecca Mueller; James F Markmann; Ali Naji
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

5.  Hyperinsulinemia after pancreatic transplantation. Prediction by a novel computer model and in vivo verification.

Authors:  R C Earnhardt; D D Kindler; A M Weaver; G Cornett; D Elahi; J D Veldhuis; J B Hanks
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

6.  Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus.

Authors:  C Alarcón; J L Leahy; G T Schuppin; C J Rhodes
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

7.  Increased C-Peptide Immunoreactivity in Insulin Autoimmune Syndrome (Hirata Disease) Due to High Molecular Weight Proinsulin.

Authors:  Richard G Kay; Peter Barker; Keith Burling; Mark Cohen; David Halsall; Frank Reimann; Fiona M Gribble; Robert K Semple; David Church
Journal:  Clin Chem       Date:  2021-06-01       Impact factor: 8.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.